glp-1/gip dual agonist lilly New findings from SURPASS-EARLY: A GIP/GLP‑1 receptor compared with intensified conventional care after two years of treatment in early type 2 diabetes. Learn more: https://t.co/W8ffAFhFtk GLP-1 Agonists in Cardiovascular Diseases:

In the market, a large number of teams are developing therapeutic drugs targeting GLP-1R, GIPR, and GCGR

To realize the full potential of GLP-1s, we need digital health

However, the two groups had no evidence of a difference in the composite incidence of MACE (HR 0.95

Third, we did not account for earlier disease stages, such as advanced chronic kidney disease, nor did we account for side-effects of these medications

Under the deal, Novo Nordisk has secured the exclusive worldwide license to use Ascendis TransCon technology platform to develop, produce, and sell products for metabolic diseases, including obesity and Type 2 diabetes with the primary goal being to develop a monthly GLP-1